NMRD - Nemaura Medical Inc Stock Price, Fair Value and News

0.04USD-0.01 (-20.00%)Market Closed

Market Summary

USD0.04-0.01

Market Closed

-20.00%

NMRD Stock Price

View Fullscreen

NMRD RSI Chart

NMRD Valuation

Market Cap

1.2M

Price/Earnings (Trailing)

-0.11

Price/Sales (Trailing)

30.01

EV/EBITDA

0.11

Price/Free Cashflow

-0.12

NMRD Price/Sales (Trailing)

NMRD Profitability

EBT Margin

-18358.00%

Return on Equity

59.75%

Return on Assets

-206.05%

Free Cashflow Yield

-842.79%

NMRD Fundamentals

NMRD Revenue

NMRD Earnings

Earnings (TTM)

-10.7M

Earnings Growth (Yr)

-25.94%

Earnings Growth (Qtr)

-79.61%

Breaking Down NMRD Revenue

Last 7 days

-33.3%

Last 30 days

-42.9%

Last 90 days

-50%

Trailing 12 Months

-95.1%

How does NMRD drawdown profile look like?

NMRD Financial Health

Current Ratio

0.19

NMRD Investor Care

Shares Dilution (1Y)

19.90%

Diluted EPS (TTM)

-0.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	397.3K	0	0	0
2022	503.9K	0	542.4K	581.0K
2021	0	0	0	380.7K
2020	257.4K	0	0	0
2019	23.9K	19.0K	11.0K	134.2K
2018	88.5K	72.4K	56.2K	40.1K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Nemaura Medical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 05, 2024	ghadar-ghadr arash	bought	14,000	0.14	100,000	chief operating officer
Jan 31, 2022	mclarney justin james	acquired	-	-	22,293	chief financial officer

Which funds bought or sold NMRD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	Blue Trust, Inc.	sold off	-100	-	-	-%
Apr 29, 2024	HAZLETT, BURT & WATSON, INC.	sold off	-100	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-12,162	27,743	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-4,000	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	9,381	9,381	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-5,248	12,075	-%
Feb 14, 2024	Alyeska Investment Group, L.P.	reduced	-54.14	-395,340	185,068	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	new	-	3,811	3,811	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	sold off	-100	-6,530	-	-%

Are Funds Buying or Selling NMRD?

Are funds buying NMRD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NMRD

No. of Funds

Unveiling Nemaura Medical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	alyeska investment group, l.p.	9.99%	2,887,050	SC 13G

Recent SEC filings of Nemaura Medical Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	8-K	Current Report
Apr 19, 2024	PRE 14C	PRE 14C
Apr 10, 2024	8-K	Current Report
Mar 21, 2024	25-NSE	25-NSE
Feb 26, 2024	8-K	Current Report
Feb 14, 2024	SC 13G	Major Ownership Report
Feb 12, 2024	10-Q	Quarterly Report

Peers (Alternatives to Nemaura Medical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	184.3B	40.3B	-5.44%	-5.22%	32.76	4.57	-2.84%	-3.08%
BDX	69.5B	19.7B	-0.20%	-8.75%	52.15	3.53	4.82%	-17.56%
ALGN	21.5B	3.9B	-8.18%	-5.47%	48.35	5.57	3.42%	23.09%
BAX	18.8B	14.9B	-13.96%	-20.60%	7.1	1.26	2.98%	207.68%
MID-CAP
ATR	9.7B	3.5B	3.73%	21.66%	30.9	2.73	6.16%	35.06%
HSIC	8.8B	12.3B	-6.12%	-14.26%	21.19	0.71	-2.44%	-22.68%
BIO	8.2B	2.7B	-15.06%	-39.81%	-12.8	3.05	-4.68%	82.43%
XRAY	5.9B	3.9B	-10.84%	-29.89%	-63.02	1.5	0.23%	91.03%
AXNX	3.4B	387.1M	-2.63%	29.53%	-215.05	8.84	30.82%	65.60%
PDCO	2.3B	6.6B	-3.75%	-4.94%	11.77	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.4B	3.2B	-4.08%	-10.47%	-2.03	0.43	7.73%	-1066.14%
ANIK	409.1M	166.7M	6.81%	6.12%	-4.95	2.45	6.67%	-456.34%
ANGO	243.5M	324.0M	-1.78%	-29.87%	-1.27	0.75	-3.19%	-337.41%
APYX	49.5M	52.3M	-3.38%	-60.28%	-2.65	0.95	17.61%	19.28%
AEMD	3.6M	3.7M	-22.16%	302.94%	-0.29	0.96	5.77%	8.23%

Nemaura Medical Inc News

Latest updates

Nemaura Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q1	2022Q4	2022Q3	2022Q1	2021Q4	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Revenue	-	-	-	3,017	74,027	320,278	183,628	122,419	61,209	-	3,926	-	7,036	8,082	8,809	-
Cost Of Revenue	-	-	-	2,971	72,357	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	100.0%	-	-1,478,108	46.00	1,670	148,371	11,235	-	-	-	-	-	-	-	-	-
Operating Expenses	-65.4%	1,541,253	4,450,149	1,623,907	1,626,216	2,590,947	1,803,619	1,346,884	1,059,369	1,117,040	1,255,191	1,624,479	932,925	1,147,357	771,963	567,776
S&GA Expenses	-57.1%	1,250,149	2,912,358	1,230,160	1,369,155	2,021,670	1,391,278	872,932	542,697	654,523	699,008	823,012	489,545	525,075	342,424	287,528
R&D Expenses	-47.8%	291,104	557,753	393,747	257,061	569,277	412,341	473,952	516,672	462,517	556,183	801,467	443,380	622,282	429,539	280,248
EBITDA Margin	100.0%	-	-261	-106	-69.37	-41.03	-1,146	-	-	-	-	-	-	-	-	-
Interest Expenses	14.8%	-1,925,678	-2,260,064	-1,082,949	-1,617,467	-1,524,928	-1,639,184	-	-	-	3,926	-	7,036	8,082	8,809	-
Income Taxes	-	-	-	-	-	-	-	-	-614,362	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-1,059,369	-	-	-	-	-	-	-
EBT Margin	100.0%	-	-183	-77.48	-49.01	-28.25	-601	-	-	-	-	-	-	-	-	-
Net Income	53.8%	-2,161,478	-4,682,847	-1,716,278	-3,855,700	-3,617,248	-3,431,568	-1,346,884	-445,007	-1,117,040	-1,251,265	-1,624,479	-925,889	-1,139,275	-763,154	-553,266
Net Income Margin	100.0%	-	-183	-71.17	-50.93	-27.56	-1,108	-	-	-	-	-	-	-	-	-
Free Cashflow	39.5%	-1,489,995	-2,462,012	-1,607,910	-2,348,288	-2,272,964	-1,016,681	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-42.0%	5.00	9.00	8.00	15.00	13.00	16.00	20.00	22.00	27.00	32.00	36.00	35.00	18.00	18.00	9.00	1.00	2.00	3.00	4.00	5.00	6.00
Current Assets	-45.8%	4.00	8.00	7.00	14.00	11.00	14.00	18.00	20.00	25.00	30.00	34.00	34.00	17.00	18.00	9.00	1.00	2.00	2.00	4.00	5.00	5.00
Cash Equivalents	-96.9%	0.00	4.00	4.00	10.00	7.00	10.00	15.00	18.00	23.00	27.00	31.00	32.00	15.00	17.00	6.00	0.00	1.00	2.00	3.00	4.00	5.00
Inventory	26.1%	4.00	3.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-
Net PPE	-4.1%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-7.2%	23.00	25.00	23.00	26.00	23.00	25.00	24.00	22.00	26.00	27.00	28.00	27.00	7.00	7.00	7.00	3.00	2.00	3.00	3.00	3.00	3.00
Current Liabilities	7.3%	23.00	21.00	22.00	22.00	13.00	20.00	18.00	21.00	16.00	17.00	12.00	6.00	4.00	3.00	4.00	1.00	1.00	1.00	1.00	1.00	1.00
Shareholder's Equity	-12.3%	-17.83	-15.87	-	-11.81	-9.86	-8.70	-	0.00	1.00	4.00	8.00	8.00	10.00	11.00	2.00	-	-	0.00	1.00	2.00	3.00
Retained Earnings	-3.9%	-57.84	-55.68	-54.48	-51.88	-47.19	-45.48	-41.62	-37.73	-34.11	-30.68	-27.19	-23.84	-21.71	-20.27	-18.69	-17.59	-16.24	-15.79	-14.68	-13.43	-11.80
Additional Paid-In Capital	0%	41.00	41.00	41.00	41.00	38.00	38.00	38.00	38.00	35.00	35.00	35.00	32.00	32.00	32.00	21.00	17.00	16.00	16.00	16.00	16.00	15.00
Shares Outstanding	0%	29.00	29.00	29.00	29.00	24.00	24.00	24.00	24.00	23.00	23.00	23.00	23.00	22.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	25.00	-	-	-	-	-	68.00	-	-	-	39.00	-	-	-	49.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	53.8%	-1,479	-3,202	-2,521	-2,361	-1,541	-2,164	-2,384	-2,150	-877	-1,786	-1,690	-1,359	-1,632	-1,928	-1,077	-885	-701	-1,170	-692	-1,242	-776
Share Based Compensation	-	-	-	-	-	-	-	-	-	-	-	-	29.00	25.00	-	59.00	247	40.00	115	162	238	85.00
Cashflow From Investing	71.9%	-10.43	-37.17	-29.21	-100	-57.64	-163	-217	-76.47	-193	-288	-398	-271	-523	-29.35	-12.28	2.00	-51.16	-74.44	-87.58	-8.23	3,095
Cashflow From Financing	-176.5%	-3,000	3,922	-3,600	5,356	-1,699	-1,500	-74.28	-2,946	-2,585	-2,300	1,464	18,506	-300	12,823	6,958	-43.48	-28.21	-1*	169	-85.79	2,135

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NMRD Income Statement

2023-12-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Sales		$ 3,017		$ 77,044
Cost of Sales		(2,971)		(75,327)
Gross Profit		46		1,717
Operating expenses:
Research and development	291,104	393,747	1,332,664	980,862
General and administrative	1,250,149	1,230,160	4,317,358	1,509,095
Total operating expenses	1,541,253	1,623,907	5,650,022	2,489,957
Loss from operations	(1,541,253)	(1,623,907)	(5,650,022)	(2,488,240)
Other income (expense)
Interest expense	(1,925,678)	(1,082,949)	(3,407,499)	(4,152,437)
Change in fair value of warrant liability	1,003,000		2,600,000
Change in fair value of foreign exchange contract derivative liability	302,453	990,532	489,435	(2,820,211)
Net loss	(2,161,478)	(1,716,278)	(5,968,086)	(9,460,888)
Other comprehensive loss:
Foreign currency translation adjustment	204,828	(556,080)	(44,327)	(864,328)
Comprehensive loss	$ (1,956,650)	$ (4,831,171)	$ (6,012,413)	$ (10,325,216)

NMRD Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Mar. 31, 2023
Current assets:
Cash and cash equivalents	$ 137,416	$ 10,105,135
Inventory	3,671,533	1,754,852
Prepaid expenses and other receivables	169,174	357,934
VAT receivable	247,788	409,648
Deposit on foreign exchange contract	146,434	909,666
Total current assets	4,372,345	13,537,235
Property and equipment, net of accumulated depreciation	558,697	641,906
Intangible assets, net of accumulated amortization	238,033	384,092
Total assets	5,169,075	14,563,233
Current liabilities:
Accounts payable	352,483	326,641
Other liabilities and accrued expenses	281,055	130,678
Notes payable, current portion	19,643,038	16,942,500
Payable to related parties	800,403	920,780
Deferred revenue, current portion	1,184,412	123,640
Foreign exchange contract derivative liability	242,295	731,730
Warrant liability	492,000	3,092,000
Total current liabilities	22,995,686	22,267,969
Notes payable, non-current portion		3,087,651
Deferred revenue, non-current portion		1,021,811
Total liabilities	22,995,686	26,377,431
Commitments and contingencies
Stockholders’ deficit:
Common stock, $0.001 par value, 42,000,000 shares authorized and 28,899,402 shares issued and outstanding at December 31, 2023 and March 31, 2023	28,899	28,899
Additional paid-in capital	40,991,377	40,991,377
Accumulated deficit	(57,843,297)	(51,875,211)
Accumulated other comprehensive loss	(1,003,590)	(959,263)
Total stockholders’ deficit	(17,826,611)	(11,814,198)
Total liabilities and stockholders’ deficit	$ 5,169,075	$ 14,563,233

About Nemaura Medical Inc

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

CEO	Dr. Dewan Fazlul Hoque Chowdhury Ph.D.
WEBSITE	https://nemauramedical.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	36

Nemaura Medical Inc Frequently Asked Questions

What is the ticker symbol for Nemaura Medical Inc? What does NMRD stand for in stocks?

NMRD is the stock ticker symbol of Nemaura Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nemaura Medical Inc (NMRD)?

As of Thu May 02 2024, market cap of Nemaura Medical Inc is 1.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NMRD stock?

You can check NMRD's fair value in chart for subscribers.

What is the fair value of NMRD stock?

You can check NMRD's fair value in chart for subscribers. The fair value of Nemaura Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Nemaura Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NMRD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Nemaura Medical Inc a good stock to buy?

The fair value guage provides a quick view whether NMRD is over valued or under valued. Whether Nemaura Medical Inc is cheap or expensive depends on the assumptions which impact Nemaura Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NMRD.

What is Nemaura Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, NMRD's PE ratio (Price to Earnings) is -0.11 and Price to Sales (PS) ratio is 30.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NMRD PE ratio will change depending on the future growth rate expectations of investors.